drugset / Trial / NCT07083323
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Phase 1/2
Recruiting
262 enrolled
Sichuan Huiyu Pharmaceutical Co., Ltd
Peking University Cancer Hospital & Institute · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced solid tumors.
Timeline
- Start
- 2025-07-22
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HY05350 | Unknown | — | Intravenous |